Nussbaum Ran
Insider CIK 1609805 · ARQL Director · ELOX Director · KITE Director · KROS Director, 10% owner · URGN Director · LBRX Director · PRVL Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LBRX LB PHARMACEUTICALS INC | A Award deriv | 2026-06-03 | 2026-06-05 | 10,000 | — | $0 | 10,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 1,121,045 | $17.75 | $19.90M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 1,226,412 | $17.75 | $21.77M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 155,262 | $17.75 | $2.76M | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2025-10-15 | 2025-10-17 | 2,284,612 | $17.75 | $40.55M | 0 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | C Conversion deriv | 2025-09-12 | 2025-09-16 | 10,000,000 | — | $0 | 0 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | P Buy | 2025-09-12 | 2025-09-16 | 1,000,000 | $15.00 | $15.00M | 1,411,681 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | C Conversion | 2025-09-12 | 2025-09-16 | 411,681 | — | $0 | 411,681 | SEC↗ |
| LBRX LB PHARMACEUTICALS INC | A Award deriv | 2025-09-10 | 2025-09-12 | 22,449 | — | $0 | 22,449 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2025-06-04 | 2025-06-06 | 10,500 | — | $0 | 10,500 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award | 2025-06-04 | 2025-06-06 | 5,250 | — | $0 | 5,250 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2024-05-30 | 2024-06-03 | 10,000 | — | $0 | 10,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2023-06-06 | 2023-06-08 | 10,000 | — | $0 | 10,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise deriv | 2022-11-29 | 2022-11-30 | 3,539 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise deriv | 2022-11-29 | 2022-11-30 | 1,914 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise deriv | 2022-11-29 | 2022-11-30 | 1,723 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise | 2022-11-29 | 2022-11-30 | 1,723 | — | $0 | 1,121,045 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise | 2022-11-29 | 2022-11-30 | 1,914 | — | $0 | 1,226,412 | SEC↗ |
| KROS Keros Therapeutics, Inc. | X Exercise | 2022-11-29 | 2022-11-30 | 3,539 | — | $0 | 2,284,612 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-10-21 | 2023-02-28 | 32,723 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-10-21 | 2023-02-28 | 15,276 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2022-10-21 | 2023-02-28 | 47,999 | $5.94 | $285.1K | 1,485,168 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-10-21 | 2022-10-25 | 32,723 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-10-21 | 2022-10-25 | 15,276 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2022-10-21 | 2022-10-25 | 47,999 | $5.94 | $285.1K | 1,481,927 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-06-16 | 2023-02-28 | 2,211 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2022-06-16 | 2023-02-28 | 2,211 | $5.00 | $11.1K | 1,437,169 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | A Award deriv | 2022-06-15 | 2022-06-17 | 20,000 | — | $0 | 20,000 | SEC↗ |
| URGN UroGen Pharma Ltd. | A Award deriv | 2022-06-08 | 2022-06-10 | 3,183 | — | $0 | 3,183 | SEC↗ |
| URGN UroGen Pharma Ltd. | A Award deriv | 2022-06-08 | 2022-06-10 | 6,817 | — | $0 | 6,817 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-06-06 | 2023-02-28 | 1,030 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2022-06-06 | 2023-02-28 | 1,030 | $5.00 | $5.2K | 1,434,958 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2022-06-06 | 2022-08-25 | 1,030 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2022-06-06 | 2022-08-25 | 1,030 | $5.00 | $5.2K | 1,433,928 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2022-06-01 | 2022-06-03 | 8,293 | — | $0 | 8,293 | SEC↗ |
| URGN UroGen Pharma Ltd. | A Award deriv | 2021-06-07 | 2021-06-09 | 6,817 | — | $0 | 6,817 | SEC↗ |
| URGN UroGen Pharma Ltd. | A Award deriv | 2021-06-07 | 2021-06-09 | 3,183 | — | $0 | 3,183 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2021-06-01 | 2021-06-03 | 8,293 | — | $0 | 8,293 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | A Award deriv | 2021-05-19 | 2021-05-20 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2021-05-13 | 2021-05-17 | 1,280,624 | $1.35 | $1.73M | 1,791,470 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2021-05-13 | 2021-05-17 | 2,630,487 | $1.35 | $3.55M | 3,679,797 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2021-05-13 | 2021-05-17 | 1,422,222 | $1.35 | $1.92M | 1,989,551 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2021-05-13 | 2021-05-17 | 592,592 | $1.35 | $800.0K | 616,592 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2021-03-25 | 2021-06-09 | 2,211 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2021-03-25 | 2021-06-09 | 1,030 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2021-03-25 | 2021-06-09 | 2,211 | $5.00 | $11.1K | 1,433,928 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2021-03-25 | 2021-06-09 | 1,030 | $5.00 | $5.2K | 1,431,717 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise deriv | 2021-03-24 | 2021-04-22 | 1,030 | — | $0 | 0 | SEC↗ |
| URGN UroGen Pharma Ltd. | M Exercise | 2021-03-24 | 2021-04-22 | 1,030 | $5.00 | $5.2K | 1,465,199 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | D To issuer deriv | 2021-01-22 | 2021-01-26 | 17,000 | — | $0 | 0 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | U Tender | 2021-01-22 | 2021-01-26 | 1,576,881 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 12,966 | $50.00 | $648.3K | 1,122,768 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 14,400 | $50.00 | $720.0K | 1,228,326 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 6,000 | $50.00 | $300.0K | 155,262 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-11-17 | 2020-11-19 | 26,634 | $50.00 | $1.33M | 2,288,151 | SEC↗ |
| PRVL Prevail Therapeutics Inc. | A Award deriv | 2020-06-17 | 2020-06-19 | 17,000 | — | $0 | 17,000 | SEC↗ |
| URGN UroGen Pharma Ltd. | A Award deriv | 2020-06-08 | 2020-06-10 | 10,000 | — | $0 | 10,000 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | A Award deriv | 2020-05-20 | 2020-05-22 | 20,000 | — | $0 | 20,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 68,654 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 91,538 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 82,425 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 737,226 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 663,825 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 1,363,542 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 36,858 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 163,612 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 88,460 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 79,653 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion deriv | 2020-04-13 | 2020-04-13 | 169,307 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 94,546 | $16.00 | $1.51M | 1,109,802 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 79,653 | — | $0 | 1,108,926 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 88,460 | — | $0 | 1,015,256 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 163,612 | — | $0 | 2,067,314 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 68,654 | — | $0 | 68,654 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 91,538 | — | $0 | 1,029,273 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 82,425 | — | $0 | 926,796 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 169,307 | — | $0 | 1,903,702 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 737,226 | — | $0 | 937,735 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 663,825 | — | $0 | 844,371 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 1,363,542 | — | $0 | 1,734,395 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 43,750 | $16.00 | $700.0K | 149,262 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 105,000 | $16.00 | $1.68M | 1,213,926 | SEC↗ |
| KROS Keros Therapeutics, Inc. | C Conversion | 2020-04-13 | 2020-04-13 | 36,858 | — | $0 | 105,512 | SEC↗ |
| KROS Keros Therapeutics, Inc. | P Buy | 2020-04-13 | 2020-04-13 | 194,203 | $16.00 | $3.11M | 2,261,517 | SEC↗ |
| ARQL ARQULE INC | D To issuer deriv | 2020-01-16 | 2020-01-16 | 40,000 | — | $0 | 0 | SEC↗ |
| ARQL ARQULE INC | D To issuer deriv | 2020-01-16 | 2020-01-16 | 30,000 | — | $0 | 0 | SEC↗ |
| ARQL ARQULE INC | D To issuer deriv | 2020-01-16 | 2020-01-16 | 20,000 | — | $0 | 0 | SEC↗ |
| ARQL ARQULE INC | U Tender | 2020-01-16 | 2020-01-16 | 2,319,920 | $20.00 | $46.40M | 0 | SEC↗ |
| ARQL ARQULE INC | U Tender | 2020-01-16 | 2020-01-16 | 4,290,550 | $20.00 | $85.81M | 0 | SEC↗ |
| ARQL ARQULE INC | U Tender | 2020-01-16 | 2020-01-16 | 2,088,816 | $20.00 | $41.78M | 0 | SEC↗ |
| ARQL ARQULE INC | U Tender | 2020-01-16 | 2020-01-16 | 36,923 | $20.00 | $738.5K | 0 | SEC↗ |
| ARQL ARQULE INC | U Tender | 2020-01-16 | 2020-01-16 | 8,611 | $20.00 | $172.2K | 0 | SEC↗ |
| ARQL ARQULE INC | M Exercise deriv | 2019-12-24 | 2019-12-27 | 400,558 | — | $0 | 0 | SEC↗ |
| ARQL ARQULE INC | M Exercise deriv | 2019-12-24 | 2019-12-27 | 823,632 | — | $0 | 0 | SEC↗ |
| ARQL ARQULE INC | M Exercise deriv | 2019-12-24 | 2019-12-27 | 445,524 | — | $0 | 0 | SEC↗ |
| ARQL ARQULE INC | F Tax w/h | 2019-12-24 | 2019-12-27 | 71,674 | $20.11 | $1.44M | 4,290,550 | SEC↗ |
| ARQL ARQULE INC | M Exercise | 2019-12-24 | 2019-12-27 | 445,524 | $1.75 | $779.7K | 2,358,690 | SEC↗ |
| ARQL ARQULE INC | F Tax w/h | 2019-12-24 | 2019-12-27 | 34,857 | $20.11 | $701.0K | 2,088,816 | SEC↗ |
| ARQL ARQULE INC | M Exercise | 2019-12-24 | 2019-12-27 | 823,632 | $1.75 | $1.44M | 4,362,224 | SEC↗ |
| ARQL ARQULE INC | F Tax w/h | 2019-12-24 | 2019-12-27 | 38,770 | $20.11 | $779.7K | 2,319,920 | SEC↗ |
| ARQL ARQULE INC | M Exercise | 2019-12-24 | 2019-12-27 | 400,558 | $1.75 | $701.0K | 2,123,673 | SEC↗ |
| ARQL ARQULE INC | X Exercise deriv | 2019-09-12 | 2019-09-16 | 27,442 | — | $0 | 400,558 | SEC↗ |
| ARQL ARQULE INC | X Exercise deriv | 2019-09-12 | 2019-09-16 | 56,368 | — | $0 | 823,632 | SEC↗ |
| ARQL ARQULE INC | X Exercise deriv | 2019-09-12 | 2019-09-16 | 30,476 | — | $0 | 445,524 | SEC↗ |
| ARQL ARQULE INC | X Exercise | 2019-09-12 | 2019-09-16 | 30,476 | $1.75 | $53.3K | 1,913,166 | SEC↗ |
| ARQL ARQULE INC | X Exercise | 2019-09-12 | 2019-09-16 | 56,368 | $1.75 | $98.6K | 3,538,592 | SEC↗ |
| ARQL ARQULE INC | X Exercise | 2019-09-12 | 2019-09-16 | 27,442 | $1.75 | $48.0K | 1,723,115 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2019-06-27 | 2019-07-01 | 36,923 | $9.75 | $360.0K | 36,923 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2019-06-27 | 2019-07-01 | 72,205 | $9.75 | $704.0K | 1,882,690 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2019-06-27 | 2019-07-01 | 65,016 | $9.75 | $633.9K | 1,695,673 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2019-06-27 | 2019-07-01 | 133,548 | $9.75 | $1.30M | 3,482,224 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2019-06-24 | 2019-06-26 | 46,933 | $9.00 | $422.4K | 567,329 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2019-06-24 | 2019-06-26 | 86,806 | $9.00 | $781.3K | 1,049,310 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2019-06-24 | 2019-06-26 | 42,261 | $9.00 | $380.3K | 510,846 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2019-06-24 | 2019-06-26 | 24,000 | $9.00 | $216.0K | 24,000 | SEC↗ |
| URGN UroGen Pharma Ltd. | A Award deriv | 2019-06-03 | 2019-06-05 | 10,000 | — | $0 | 10,000 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | A Award deriv | 2019-05-29 | 2019-05-29 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | A Award deriv | 2019-05-29 | 2019-05-30 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ARQL ARQULE INC | A Award deriv | 2019-05-14 | 2019-05-15 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2018-07-13 | 2018-10-22 | 89,676 | $5.50 | $493.2K | 3,348,676 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2018-07-13 | 2018-10-22 | 48,485 | $5.50 | $266.7K | 1,810,485 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2018-07-13 | 2018-10-22 | 43,657 | $5.50 | $240.1K | 1,630,657 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | A Award deriv | 2018-06-15 | 2018-06-19 | 40,000 | — | $0 | 40,000 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2018-05-18 | 2018-05-18 | 8,611 | $3.29 | $28.3K | 8,611 | SEC↗ |
| ARQL ARQULE INC | P Buy | 2018-05-18 | 2018-05-22 | 8,611 | $3.29 | $28.3K | 8,611 | SEC↗ |
| ARQL ARQULE INC | A Award deriv | 2018-05-08 | 2018-05-10 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ARQL ARQULE INC | J Other deriv | 2018-05-08 | 2018-05-25 | 476,000 | — | $0 | 476,000 | SEC↗ |
| ARQL ARQULE INC | J Other deriv | 2018-05-08 | 2018-05-25 | 428,000 | — | $0 | 428,000 | SEC↗ |
| ARQL ARQULE INC | J Other deriv | 2018-05-08 | 2018-05-25 | 880,000 | — | $0 | 880,000 | SEC↗ |
| ARQL ARQULE INC | J Other | 2018-05-08 | 2018-05-25 | 1,587,000 | — | $0 | 1,587,000 | SEC↗ |
| ARQL ARQULE INC | J Other | 2018-05-08 | 2018-05-25 | 1,762,000 | — | $0 | 1,762,000 | SEC↗ |
| ARQL ARQULE INC | J Other | 2018-05-08 | 2018-05-25 | 3,259,000 | — | $0 | 3,259,000 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-04-30 | 2018-05-01 | 172,626 | $9.75 | $1.68M | 962,504 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-04-30 | 2018-05-01 | 93,333 | $9.75 | $910.0K | 520,396 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-04-30 | 2018-05-01 | 84,041 | $9.75 | $819.4K | 468,585 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-03-22 | 2018-03-23 | 2,959 | $8.00 | $23.7K | 789,878 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-03-22 | 2018-03-23 | 1,441 | $8.00 | $11.5K | 384,544 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-03-22 | 2018-03-23 | 1,600 | $8.00 | $12.8K | 427,063 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-03-21 | 2018-03-23 | 1,760 | $7.55 | $13.3K | 425,463 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-03-21 | 2018-03-23 | 1,585 | $7.55 | $12.0K | 383,103 | SEC↗ |
| ELOX Eloxx Pharmaceuticals, Inc | P Buy | 2018-03-21 | 2018-03-23 | 3,255 | $7.55 | $24.6K | 786,919 | SEC↗ |
| ARQL ARQULE INC | A Award deriv | 2017-11-08 | 2017-11-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer deriv | 2017-10-03 | 2017-10-05 | 50,000 | $178.65 | $8.93M | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer deriv | 2017-10-03 | 2017-10-05 | 7,000 | $129.13 | $903.9K | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer deriv | 2017-10-03 | 2017-10-05 | 10,000 | $120.77 | $1.21M | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer deriv | 2017-10-03 | 2017-10-05 | 8,810 | $88.79 | $782.2K | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer | 2017-10-03 | 2017-10-05 | 2,651 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer | 2017-10-03 | 2017-10-05 | 1,029 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer | 2017-10-03 | 2017-10-05 | 2,632 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer | 2017-10-03 | 2017-10-05 | 3,520 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | D To issuer | 2017-10-03 | 2017-10-05 | 4,360 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | A Award deriv | 2017-06-20 | 2017-06-22 | 8,810 | — | $0 | 8,810 | SEC↗ |
| KITE Kite Pharma, Inc. | A Award | 2017-06-20 | 2017-06-22 | 2,410 | — | $0 | 4,360 | SEC↗ |
| KITE Kite Pharma, Inc. | P Buy | 2017-05-09 | 2017-05-11 | 1,029 | $69.17 | $71.2K | 1,029 | SEC↗ |
| KITE Kite Pharma, Inc. | P Buy | 2017-05-09 | 2017-05-11 | 2,651 | $69.17 | $183.4K | 2,651 | SEC↗ |
| KITE Kite Pharma, Inc. | P Buy | 2017-05-09 | 2017-05-11 | 3,520 | $69.17 | $243.5K | 3,520 | SEC↗ |
| KITE Kite Pharma, Inc. | P Buy | 2017-05-09 | 2017-05-11 | 2,632 | $68.94 | $181.5K | 2,632 | SEC↗ |
| KITE Kite Pharma, Inc. | A Award deriv | 2016-06-01 | 2016-06-03 | 7,000 | — | $0 | 7,000 | SEC↗ |
| KITE Kite Pharma, Inc. | A Award | 2016-06-01 | 2016-06-03 | 1,950 | — | $0 | 1,950 | SEC↗ |
| KITE Kite Pharma, Inc. | A Award deriv | 2015-06-09 | 2015-06-17 | 10,000 | — | $0 | 10,000 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-06-02 | 2015-06-03 | 24,070 | $56.08 | $1.35M | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-06-02 | 2015-06-03 | 200,604 | $55.27 | $11.09M | 24,070 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-06-01 | 2015-06-03 | 7,800 | $57.38 | $447.6K | 224,674 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-06-01 | 2015-06-03 | 3,754 | $56.44 | $211.9K | 232,474 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-06-01 | 2015-06-03 | 69,206 | $55.05 | $3.81M | 236,228 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-03-30 | 2015-03-31 | 23,349 | $59.91 | $1.40M | 112,714 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-03-30 | 2015-03-31 | 66,948 | $59.91 | $4.01M | 149,116 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-03-30 | 2015-03-31 | 25,560 | $59.91 | $1.53M | 43,604 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-03-27 | 2015-03-31 | 13,936 | $61.24 | $853.4K | 216,064 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-03-27 | 2015-03-31 | 13,937 | $61.24 | $853.5K | 136,063 | SEC↗ |
| KITE Kite Pharma, Inc. | S Sale | 2015-03-27 | 2015-03-31 | 50,000 | $61.24 | $3.06M | 70,000 | SEC↗ |
| KITE Kite Pharma, Inc. | C Conversion deriv | 2014-06-25 | 2014-06-27 | 807,681 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | C Conversion deriv | 2014-06-25 | 2014-06-27 | 1,072,245 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | C Conversion deriv | 2014-06-25 | 2014-06-27 | 313,531 | — | $0 | 0 | SEC↗ |
| KITE Kite Pharma, Inc. | C Conversion | 2014-06-25 | 2014-06-27 | 810,803 | — | $0 | 810,803 | SEC↗ |
| KITE Kite Pharma, Inc. | C Conversion | 2014-06-25 | 2014-06-27 | 1,076,390 | — | $0 | 1,076,390 | SEC↗ |
| KITE Kite Pharma, Inc. | C Conversion | 2014-06-25 | 2014-06-27 | 314,743 | — | $0 | 314,743 | SEC↗ |